Differentiated Thyroid Cancer with a Focus on Adverse Event Management

Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.

EP. 1: Overview of RAI-Refractory DTC

January 21st 2021

Steven Sherman, MD, FACE, provides an overview of the history and evolution of treating patients with RAI [radioactive iodine]–refractory differentiated thyroid cancer [DTC].

EP. 2: Phase 3 SELECT Trial

January 21st 2021

A review of the phase 3 SELECT trial examining the use of lenvatinib for the treatment of RAI-refractory DTC and the management of adverse events.

EP. 3: Dosing of TKI Therapy for RAI-Refractory DTC

January 21st 2021

A review of a multicenter phase 2 study evaluating the safety and efficacy of lenvatinib starting doses in RAI-refractory DTC.

EP. 4: Managing Adverse Events in RAI-Refractory DTC Therapy

January 21st 2021

An expert endocrinologist perspective on managing the toxicities associated with lenvatinib when treating RAI-refractory DTC and the role of dose reduction and interruption.

EP. 5: RAI-Refractory DTC: Patient Education of Systemic Therapy

January 21st 2021

Approaching patient education of RAI-refractory DTC therapy with lenvatinib, fostering open communication between patients and providers, and monitoring medication adherence.

EP. 6: Future Treatment Landscape of RAI-Refractory DTC

January 21st 2021

Steven Sherman, MD, FACE, provides closing thoughts on unmet needs and future directions for the treatment of patients with RAI-refractory DTC.